Hadas Alterman is a leading legal advocate in the psychedelic industry, with experience advising businesses, investors, and nonprofits navigating the emerging regulated market. As co-founder of Plant Medicine Law Group LLP, she built a boutique firm to support psychedelic-assisted therapy clinics, retreat centers, training programs, drug development companies, and media organizations.
Hadas is an advisor to the Texas Ibogaine Initiative. Previously, she was the Director of Communications & Policy for the American Psychedelic Practitioners Association. Hadas has played an active role in shaping psychedelic legalization at the state level, as a member of the Oregon Psilocybin Advisory Board for Measure 109 in Oregon, and Natural Medicine Advisory Board for Proposition 112 in Colorado. She was also a Founding Board Member of the Psychedelic Bar Association.
Hadas has counseled clients on regulatory compliance, corporate governance, clinical trial agreements, fundraising, and licensing. Her work has also included advising ketamine-assisted therapy clinics, psilocybin retreat operators, and psychedelic research organizations, and she has provided legal risk assessment for nonprofits focused on access, integration support, and Indigenous rights advocacy in psychedelic medicine. She has also represented psychedelic-focused funds, biotech companies, and media platforms, helping to shape the legal and business infrastructure of this rapidly evolving industry.
